MedTrace Logo

To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers

NCT07374406 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-04-23

No results posted yet for this study

Summary

A randomized, open-label, single dose, 2x2 crossover study to evaluate the safety and pharmacokinetic characteristics after administration of Epaminurad in healthy adult volunteers under fasting conditions

Conditions

  • Healthy

Interventions

DRUG

Epaminurad 9 mg (JW Pharmaceutical)

Test product. A single oral dose of 1 tablet containing 9 mg of Epaminurad.

DRUG

Epaminurad 9 mg (Shanghai STA Pharmaceutical)

Reference product. A single oral dose of 1 tablet containing 9 mg of Epaminurad.

Sponsors & Collaborators

Principal Investigators

  • Seol Ju Moon · Jeonbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-02
Primary Completion
2026-02-19
Completion
2026-02-24

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07374406 on ClinicalTrials.gov